STOCK TITAN
  1. Home
  2. News
  3. NARI

Inari Medical, Inc. - NARI STOCK NEWS

Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.

Inari Medical, Inc. (NASDAQ: NARI) is a leading medical device company dedicated to developing innovative solutions for the interventional treatment of vascular thrombi and emboli. The company's mission centers on improving the lives of patients suffering from venous and other related diseases through the design and production of advanced medical devices.

Inari Medical's product portfolio includes several key devices:

  • ClotTriever: Designed for the removal of clots from peripheral blood vessels, primarily treating patients with deep vein thrombosis (DVT).
  • FlowTriever System: Used for the treatment of pulmonary embolism (PE).
  • InThrill System: Aimed at treating small vessel thrombosis.
  • LimFlow System: Another innovative solution recently added to their portfolio through acquisition.

The company operates extensively within the United States but also generates significant revenue from international markets. Inari Medical's dedication to clinical research and patient education is evident in their continuous efforts to generate high-quality clinical data to support their products.

In recent news, Inari Medical announced the PEERLESS II RCT, a major clinical study involving up to 1,200 patients. This study aims to influence global guidelines for treating intermediate-risk PE patients. Inari's fourth-quarter financial results showed a substantial revenue increase, driven by the strong adoption of their procedures, new product launches, and global commercial expansion. The company reported $132.1 million in revenue for Q4 2023, marking a 22.6% increase year-over-year.

Additionally, Inari Medical has undertaken significant legal action to protect its intellectual property. The company filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc., seeking injunctive relief and damages for infringement on eight of its patents.

Guided by principles such as putting patients first and fostering innovation, Inari Medical continues to advance its mission of establishing its treatments as the standard of care for venous thromboembolism and beyond.

News

Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance

Rhea-AI Summary
Inari Medical, Inc. (NARI) reported preliminary unaudited fourth quarter revenue of at least $132.0 million, up 22% year-over-year and full year revenue of at least $493.5 million, up 29% over 2022. The company also established its 2024 financial guidance, expecting revenue of $580 million to $595 million and reaching sustained operating profitability in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.08%
Tags
none
-
News

OKAMI MEDICAL APPOINTS RHONDA ROBB AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Rhea-AI Summary
Okami Medical Inc. (Ticker: OMI) appoints Rhonda Robb as President and CEO, bringing over 25 years of leadership and commercial experience in the medical device industry. The company is preparing to commercialize the LOBO Vascular Occlusion System, a next-generation technology addressing peripheral vascular conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
management
-
News

Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
conferences
News

Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT)

Rhea-AI Summary
Inari Medical, Inc. (NARI) announced the first patient enrollment in the PEERLESS II study, a global clinical trial comparing the outcomes of intermediate-risk acute pulmonary embolism patients treated with the FlowTriever® System against traditional anticoagulation therapy. The study aims to generate evidence to influence PE treatment guidelines worldwide and establish FlowTriever as the optimal therapy for intermediate-risk PE patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
News

Inari Medical Closes Acquisition of LimFlow

Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) announced the completion of its acquisition of LimFlow S.A., a pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). The acquisition, valued at $250 million in upfront cash, with potential additional payments of up to $165 million, aligns with Inari's mission to treat patients suffering from venous and other diseases. The integration of LimFlow's technology is expected to address a significant unmet need in vascular medicine and enhance Inari's growth portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
acquisition
-
News

Inari Medical to Present at Upcoming Investor Conferences

Rhea-AI Summary
Inari Medical, Inc. (NASDAQ: NARI) announced that its management team will be presenting at two investor conferences. The first presentation will be at the Jefferies London Healthcare Conference on November 15 in London, England. The second presentation will be at the 35th Annual Piper Sandler Healthcare Conference on November 29 in New York, NY. The presentations will be available for live audio webcasts and replays on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
conferences
News

LimFlow Announces Agreement to Be Acquired by Inari Medical

Rhea-AI Summary
LimFlow, a pioneer in minimally-invasive technology for treating chronic limb-threatening ischemia (CLTI), will be acquired by Inari Medical for a total potential transaction value of up to $415 million. LimFlow will receive $250 million in cash at closing and up to $165 million in additional payments based on milestones. The acquisition is expected to increase patient access to LimFlow's technology for CLTI patients. The LimFlow System is the first and only FDA-approved device for Transcatheter Arterialization of the Deep Veins (TADV).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.97%
Tags
acquisition
-
News

Inari Medical Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Inari Medical reported financial results for Q3 2023, with revenue of $126.4 million, up 31.4% YoY. They also achieved net income of $3.2 million compared to a net loss of $10.2 million in the same quarter last year. The company ended the quarter with cash and investments of $351.3 million. Inari also announced the acquisition of LimFlow, a pioneer in limb salvage for patients with chronic limb-threatening ischemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.97%
Tags
earnings
-
News

Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow

Rhea-AI Summary
Inari Medical, Inc. has announced its Q3 2023 financial results and its agreement to acquire LimFlow, S.A. for $250 million in cash. LimFlow is a pioneer in limb salvage for patients with chronic limb-threatening ischemia. The acquisition is expected to close in Q4 2023. LimFlow recently received FDA approval for its Transcatheter Arterialization of Deep Veins system. The CLTI market is large and underpenetrated, impacting over 1.5 million patients globally. Inari sees this acquisition as aligned with its mission and expects it to bring clinically differentiated solutions and enhance growth opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.97%
Tags
acquisition
News

Inari Medical to Announce Third Quarter 2023 Financial Results

Rhea-AI Summary
Inari Medical, Inc. to release Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.23%
Tags
earnings

FAQ

What is the current stock price of Inari Medical (NARI)?

The current stock price of Inari Medical (NARI) is $49.66 as of November 22, 2024.

What is the market cap of Inari Medical (NARI)?

The market cap of Inari Medical (NARI) is approximately 2.9B.

What does Inari Medical, Inc. specialize in?

Inari Medical specializes in developing medical devices for the interventional treatment of vascular thrombi and emboli, including solutions for deep vein thrombosis and pulmonary embolism.

What are the key products in Inari Medical's portfolio?

The key products include ClotTriever, FlowTriever System, InThrill System, and LimFlow System, each designed to treat various types of vascular conditions.

Where does Inari Medical generate most of its revenue?

Inari Medical generates the majority of its revenue in the United States, with additional income from international markets.

What recent clinical study has Inari Medical announced?

Inari Medical announced the PEERLESS II RCT, a clinical study involving up to 1,200 patients to help change global guidelines for treating intermediate-risk pulmonary embolism patients.

How did Inari Medical perform financially in the fourth quarter of 2023?

In the fourth quarter of 2023, Inari Medical reported a revenue of $132.1 million, an increase of 22.6% compared to the same period in the previous year.

What is Inari Medical's approach to innovation?

Inari Medical is committed to improving lives through innovative solutions for unmet and underrecognized health needs, focusing on clinical research and patient education.

Who should investors contact for more information?

Investors can contact John Hsu, CFA, VP of Investor Relations at 949-658-3889 or via email at IR@inarimedical.com.

What legal actions has Inari Medical recently taken?

Inari Medical filed a patent infringement lawsuit against Imperative Care, Inc. and Truvic Medical, Inc. for infringing on eight of its patents related to thrombectomy devices.

What are Inari Medical's guiding principles?

Inari's guiding principles include putting patients first, planning big, and taking care of each other.

How can interested parties access Inari Medical's live events?

Interested parties can access live events via telephone by dialing provided numbers or by visiting the Events Section of Inari’s investor relations website.

Stock NARI logo
Inari Medical, Inc.

Nasdaq:NARI

NARI Rankings

#1715 Ranked by Market Cap
N/A Ranked by Dividends

NARI Stock Data

2.94B
53.44M
8.75%
95.57%
6.31%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
IRVINE